someone asked earlier what revenue was expected from hep e deal. In Nov last year Shaw's did a report on slt which estimated $US400,000 in 2004 revenue for slt on the sale of hep e test kits. It estimated that revenue would rise to $US800,000 in 2005.
hep A is where it gets interesting ... $US2.5million for 2004 (if a deal got done) and $4million 2005.
So combined revenue for hep e and a of $2.9m in 2004 and $6.8m in 2005.
They claimed the first year of any hep c test kit in 2005. would provide $2million in revenue.
Obviously this is all based on estimates, and the timeline has been setback somewhat, but gives an idea of why hep e is the first step. It also doesn't include any value that may come out of anti-virals, peptides or assays that burnett istitute is working on.
SLT Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held
